The mean follow-up was 4.81.1 years for the GLP-1RAs group and 5.31.2 years for the SGLT2 inhibitors group
Chan CY, Mong MC, Liu WH, Huang CY, Yin MC
AOD9604 is studied for stimulating fat breakdown specifically, without the bone growth, muscle growth, or insulin resistance effects typically associated with full-length growth hormone administration
2025 NCT06354660 TRANSCEND-T2D-1 Phase 3 clinical trial
[VOLVER AL INDICE | ORLISTAT QU ES Y PARA QU SIRVE] Qu necesitas saber antes de empezar a tomar Normofit Ya os hemos explicado Orlistat qu es y para qu sirve: Normofit
This durability points to Revitas potential as an important new strategy for long-term metabolic health and a new path forward for patients seeking to stay off chronic drug therapy. These new data underscore Revitas potential to support weight maintenance after GLP-1 discontinuation, said Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of Fractyl Health
